Merck: FDA Approves Vaxneuvance Vaccine in Infants, Children
June 22 2022 - 7:27AM
Dow Jones News
By Colin Kellaher
Merck & Co. on Wednesday said the U.S. Food and Drug
Administration approved the expanded use of its Vaxneuvance
15-valent pneumococcal vaccine to include children and infants as
young as six weeks of age.
The Kenilworth, N.J., drugmaker said the expanded indication
makes Vaxneuvance the first pneumococcal conjugate vaccine approved
in almost a decade to help protect pediatric populations against
invasive pneumococcal disease.
Merck said a U.S. Centers for Disease Control and Prevention
advisory committee is slated to meet later on Wednesday to discuss
and make recommendations on the use of Vaxneuvance in children.
Merck last year received FDA approval of the vaccine for
adults.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 22, 2022 07:12 ET (11:12 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024